

Hypertrophic
Cardiomyopathy:
At the
intersection of
sex and race


Neal K Lakdawala, MD
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Disclosures

- Organizations – American Heart Association (Vice Chair, Council on Scientific Sessions; Genomics and Precision Medicine)
- Consulting – Pfizer, Array, MyoKardia, Bristol Meyers Squibb, Tenaya, Sarepta
- Research support – O’Hare, Steggall and McKenzie Family Foundations



Core genetic principals of hypertrophic cardiomyopathy (HCM) 101



HCM is the most common genetic heart disease (1:500)

HCM is caused by sarcomere gene mutations (variants) with autosomal dominant inheritance


The penetrance of sarcomere gene mutations is age dependent

The expression of sarcomere gene mutations is highly variable



The influence of sex and race on HCM penetrance and expression is incompletely understood

Women are underrepresented at HCM Centers Across the Globe

- Women account for 38% of patients at specialized HCM centers
 - Disparate access to care - ***Societal?***
 - Non-sex-based diagnostic thresholds - ***Institutional?***
 - Lower sarcomere gene penetrance - ***Biological?***




Women with HCM: Older and more likely to have a sarcomere gene mutation




Sex based differences in the age of diagnosis vary by genetic substrate in HCM

	Female		Male		p-value
	N	Age (SD)	N	Age (SD)	
Sarc -	549	53.0 (18.6)	1039	45.9 (17.3)	<0.0001
Sarc +	701	38.7 (18.3)	1016	35.1 (16.7)	<0.0001
MYBPC3	363	41.5 (16.8)	609	36.8 (16.0)	<0.0001
MYH7	220	34.8 (19.2)	272	33.3 (16.8)	0.387
Thin filament	84	37.6 (18.3)	86	30.9 (19.4)	0.021

Women with HCM are more likely to die and develop advanced heart failure



Female	2,222	1,315	933	680	482	333
Male	3,644	2,165	1,582	1,152	843	556
	Patients at risk					



Female	1,754	951	641	466	336	224
Male	3,124	1,743	1,234	882	652	426
	Patients at risk					

Sex-based
Disparities
in HCM
*Where do
we go?*

Model system studies: Include sex as a variable, study the effect of sex hormones

Diagnosis: Prospective studies of penetrance, improve access to specialized care, reassess diagnostic thresholds

Outcomes: Detailed studies of septal reduction therapy, myosin inhibition, and heart failure related to HCM with sex as a variable

Black Patients with HCM: Underrepresented and more symptomatic

Underrepresented: Lower representation in US HCM specialty clinics than predicted (8.3% Black, 205/2467), *29% of predicted*

Younger at diagnosis (37 vs. 42 years) with **more hypertension** (37% vs. 26%) but similar LVH and outflow tract obstruction

Less likely to have **genetic testing** (54% vs. 62%) and less likely to have (26% vs. 41%) **sarcomere mutation**

Table 3. Multivariable Model Examining Association of Race With NYHA Class III or IV Heart Failure Among 1422 Black and White Patients

Variable	Hazard Ratio (95% CI)	P Value
Black race	1.97 (1.34-2.88)	<.001
Age at diagnosis	1.02 (1.01-1.03)	<.001
Hypertension	1.01 (0.78-1.29)	.96
Obstruction ^a	1.81 (1.42-2.31)	<.001
Sarcomere status ^b		
Sarcomere positive	1.69 (1.30-2.20)	<.001
Sarcomere VUS	1.61 (1.08-2.39)	.02
Body mass index	1.06 (1.05-1.08)	<.001

Abbreviation: VUS, variants of unknown significance.

^a Left ventricular outflow tract gradient >30 mm Hg on baseline echocardiography.

^b Sarcomere-positive patients with pathogenic or likely pathogenic mutations on any of the 8 sarcomere-encoding genes; *ACTC1* (OMIM 102540), *MYBPC3* (OMIM 600958), *MYH7* (OMIM 160760), *MYL2* (OMIM 160781), *MYL3* (OMIM 160790), *TNNI3* (OMIM 191044), *TNNT2* (OMIM 191045), and *TPM1* (OMIM 191010). Sarcomere VUS is defined as patients with VUS in any of the 8 sarcomere-encoding genes. Total event rate was 304 events.

Systematic solutions for Black Patients with HCM

1

Policy makers

Improve access to specialty care

2

Cardiology community

Address preconceptions about hypertensive heart disease

3

Genomics Community

Improve the ancestral diversity of reference populations